planes de pago
¿Quieres analizar varias empresas a la vez? Los planes de pago te permiten comparar hasta 5 acciones lado a lado.
Regístrate
A
ATTO
vs
S&P 500
S&P 500
En los últimos 12 meses, ATTO ha quedado por detrás de S&P 500, ofreciendo una rentabilidad de -25% frente a S&P 500de +19% crecimiento.
Rendimiento de las acciones
ATTO vs S&P 500
Diferencia de rendimiento
ATTO vs S&P 500
Rendimiento por año
ATTO vs S&P 500
Compara la rentabilidad de la acción con su índice de referencia y sus competidores. Obtén información sobre su rendimiento relativo a lo largo del tiempo.
Rendimiento de los competidores
Attovia Therapeutics Inc vs pares
Attovia Therapeutics Inc
Vista general
Attovia Therapeutics Inc is a US-based company operating in industry. The company is headquartered in San Carlos, California. The company went IPO on 2026-08-05. Attovia Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases with high unmet need. Its lead pipeline candidates target commercially validated pathways and are designed through its ATTOBODY biologics platform to deliver improved treatments relative to the standards of care. Its ATTOBODY platform uses an evolution-driven, high-throughput process which allows for discovery and creation of a high diversity of potential product candidates. The company is developing a pipeline of novel biotherapeutics for the treatment of immune-mediated diseases. Its first two product candidates for its immune-dermatology franchise, ATTO-1310 and ATTO-2306, have the potential to treat patients suffering from pruritic and lesional diseases. Its third program, ATTO-1091, broadens its reach to other inflammatory diseases, such as IBD, a therapeutic area with substantial unmet need. ATTO-1310 is an ATTOBODY-based therapeutic targeting interleukin-31.